Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intellipharmaceutics (IPCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 76,119
  • Shares Outstanding, K 30,570
  • Annual Sales, $ 2,250 K
  • Annual Income, $ -10,140 K
  • 36-Month Beta 1.05
  • Price/Sales 32.93
  • Price/Cash Flow 0.00
  • Price/Book 91.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.04 +22.06%
on 06/29/17
2.92 -14.73%
on 07/11/17
+0.30 (+13.70%)
since 06/23/17
3-Month
1.85 +34.59%
on 06/01/17
2.92 -14.73%
on 07/11/17
+0.60 (+31.75%)
since 04/25/17
52-Week
1.58 +57.59%
on 07/26/16
3.35 -25.67%
on 11/25/16
+0.87 (+53.70%)
since 07/25/16

Most Recent Stories

More News
IIROC Trade Halt - Intellipharmaceutics International Inc.

The following issues have been halted by IIROC:

IPCI : 2.49 (+2.89%)
Intellipharmaceutics International (IPCI) Jumps: Stock Up 19%

Intellipharmaceutics International Inc. (IPCI) shares rose around 19% in the last trading session.

PETX : 7.25 (+1.68%)
IPCI : 2.49 (+2.89%)
Key FDA Events to Watch Out for in Jul 2017

Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?

PBYI : 95.35 (-0.52%)
EGRX : 70.04 (-3.79%)
NVS : 84.20 (-0.11%)
AMGN : 180.89 (-0.09%)
UCBJF : 69.2000 (+0.79%)
IPCI : 2.49 (+2.89%)
OCUL : 6.42 (-2.87%)
Intellipharmaceutics Announces Launch of Generic Seroquel XR

Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited...

AZN : 33.78 (-0.21%)
ENDP : 11.55 (-1.03%)
MNK : 47.42 (+0.59%)
IPCI : 2.49 (+2.89%)
Intellipharmaceutics Announces Launch of Generic Seroquel XR(R) by Mallinckrodt

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel...

IPCI.TO : 3.10 (+2.31%)
IPCI : 2.49 (+2.89%)
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

IPCI.TO : 3.10 (+2.31%)
IPCI : 2.49 (+2.89%)
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR(R) by Par Pharmaceutical

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

IPCI.TO : 3.10 (+2.31%)
IPCI : 2.49 (+2.89%)
Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR(R)

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel...

IPCI.TO : 3.10 (+2.31%)
IPCI : 2.49 (+2.89%)
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected

IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss...

AZN : 33.78 (-0.21%)
ENDP : 11.55 (-1.03%)
NVS : 84.20 (-0.11%)
IPCI : 2.49 (+2.89%)
Intellipharmaceutics Announces First Quarter 2017 Results

Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

IPCI.TO : 3.10 (+2.31%)
IPCI : 2.49 (+2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including...

See More

Support & Resistance

2nd Resistance Point 2.58
1st Resistance Point 2.53
Last Price 2.49
1st Support Level 2.42
2nd Support Level 2.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.